{
    "Clinical Trial ID": "NCT00777101",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Neratinib",
        "  Neratinib",
        "  Neratinib: Tablets, 240mg once per day until disease progression or unacceptable toxicity",
        "INTERVENTION 2: ",
        "  Lapatinib+Capecitabine",
        "  Lapatinib plus Capecitabine",
        "  Lapatinib: Tablets 1250mg once per day until disease progression or unacceptable toxicity.",
        "  Capecitabine: Tablets 2000mg/m2 given in two evenly divided daily doses for first 14 days of each 21 day cycle. Given until disease progression or unacceptable toxicity."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Stage IIIB, IIIC, or IV erbB2 (HER2) positive breast cancer",
        "  Prior use of Herceptin (trastuzumab), and a taxane",
        "  Adequate cardiac and renal function",
        "Exclusion Criteria:",
        "  More than 2 prior Herceptin (trastuzumab) regimens or prior use of Xeloda (capecitabine) and / or Tykerb (lapatinib) [Tyverb]",
        "  Bone as the only site of disease",
        "  Active central nervous system metastases (subjects should be stable and off anticonvulsants and steroids)",
        "  Significant gastrointestinal disorder with diarrhea as major symptom"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Progression Free Survival",
        "  Progression Free Survival, Measured in Months, for Subjects Randomized. Investigator assessment. The time interval from the date of randomization until the earliest date of progression per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) or death due to any cause. For subjects without death or progression, censorship was at the last valid tumor assessment.",
        "  Time frame: From randomization date to progression or death, assessed up to 69 months",
        "Results 1: ",
        "  Arm/Group Title: Neratinib",
        "  Arm/Group Description: Neratinib",
        "  Neratinib: Tablets, 240mg once per day until disease progression or unacceptable toxicity",
        "  Overall Number of Participants Analyzed: 117",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  4.53        (3.12 to 5.65)",
        "Results 2: ",
        "  Arm/Group Title: Lapatinib+Capecitabine",
        "  Arm/Group Description: Lapatinib plus Capecitabine",
        "  Lapatinib: Tablets 1250mg once per day until disease progression or unacceptable toxicity.",
        "  Capecitabine: Tablets 2000mg/m2 given in two evenly divided daily doses for first 14 days of each 21 day cycle. Given until disease progression or unacceptable toxicity.",
        "  Overall Number of Participants Analyzed: 116",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  6.83        (5.85 to 8.21)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 31/116 (26.72%)",
        "  Neutropenia 1/116 (0.86%)",
        "  Thrombocytopenia 1/116 (0.86%)",
        "  Acute myocardial infarction 1/116 (0.86%)",
        "  Myocardial infarction 0/116 (0.00%)",
        "  Pericardial effusion 0/116 (0.00%)",
        "  Abdominal pain 3/116 (2.59%)",
        "  Ascites 1/116 (0.86%)",
        "  Diarrhoea 3/116 (2.59%)",
        "  Gingival bleeding 1/116 (0.86%)",
        "  Intestinal haemorrhage 1/116 (0.86%)",
        "  Nausea 2/116 (1.72%)",
        "Adverse Events 2:",
        "  Total: 24/115 (20.87%)",
        "  Neutropenia 1/115 (0.87%)",
        "  Thrombocytopenia 0/115 (0.00%)",
        "  Acute myocardial infarction 0/115 (0.00%)",
        "  Myocardial infarction 1/115 (0.87%)",
        "  Pericardial effusion 1/115 (0.87%)",
        "  Abdominal pain 0/115 (0.00%)",
        "  Ascites 0/115 (0.00%)",
        "  Diarrhoea 4/115 (3.48%)",
        "  Gingival bleeding 0/115 (0.00%)",
        "  Intestinal haemorrhage 0/115 (0.00%)",
        "  Nausea 3/115 (2.61%)"
    ]
}